Eli Lilly and Company (VIE:LLYC)

Market Cap	818.89B
Revenue (ttm)	50.64B
Net Income (ttm)	15.69B
Shares Out	n/a
EPS (ttm)	17.42
PE Ratio	52.18
Forward PE	34.37
Dividend	5.35 (0.59%)
Ex-Dividend Date	Nov 14, 2025

Volume	17
Average Volume	74
Open	905.70
Previous Close	907.30
Day's Range	901.70 - 919.70
52-Week Range	539.10 - 965.00
Beta	n/a
RSI	62.13
Earnings Date	Feb 6, 2026

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja...

• Industry: Pharmaceutical Preparations
• Founded: 1876
• Employees: 47,000
• Stock Exchange: Vienna Stock Exchange
• Ticker Symbol: LLYC

Financial Performance

In 2024, Eli Lilly and Company's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.

Financial numbers in USD